A Great Fiducial Marker That Helps Improve Radiotherapy & Surgery
Minimally invasive
Industry leading thin needles
Great Visibility
Easily register kV, CT and MR images
Instant Stability
Multiple cut-outs allow the marker to fold
A fiducial marker made in Sweden
The Gold Anchor has been invented and developed by Ingemar Naslund, M.D, Associate Professor, working as head of the Division of Radiation Therapy, Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden for 20 years, where he was one of the inventors of the SBRT technique in 1991 together with Ingmar Lax and Henric Blomgren.
Safe to use in almost any inner organ
- Prostate
- Breast
- Liver
- Pancreas
- Kidney
- Adrenal gland
- Lung
- Cervix and other gynecologic organs
- Oligomets in abdomen
- Inguinal metastases
- Head & neck
- Etc.
- Not for use in eye or central nerve system
Gold Anchor fiducial markers in prostate, automatically detected by Varian TrueBeam®
Images courtesy of the Sahlgrenska University Hospital
Enabling state of the art radiotherapy
- Intrafraction Motion Management
- Onboard kV-imaging
- Elekta XVI seed match
- Varian TrueBeam Auto-Beam-Hold
- Particle Therapy
- Synchrony CyberKnife & Radixact
- Brainlab ExacTrac Dynamic
- Frameless SBRT
- Tomotherapy
- CT/MRI fusion
Ideal for surgery and biopsy marking
- Breast biopsy clip-marking
- Surgical guidance of pancreatic tumours
- Marking of lung nodules prior to lung surgery
- Intraoperative localisation during spinal surgery
- Endoscopic placement with the Gold Anchor Introducer
Mammogram showing Gold Anchor implanted in breast to mark a biopsy site
 Financially beneficial
Fiducial marker based IGRT vs. CBCT (without markers)
- Faster, safer and easier positioning using either orthogonal 2D images or marker detection software on kV/CBCT.
- Enabling tracking of intrafraction motion.
- Providing confidence to hypofractionate.
Gold Anchor vs. traditional fiducial markers
- Reduced complications from implantation.
- Less costly to implant percutaneously than endoscopically.
- Shorter lead times.